Cargando…

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis

Two systematic reviews summarized the efficacy and safety of pharmacological prophylaxis for venous thromboembolism (VTE) after hepatic resection, but both lacked a discussion of the differences in the pharmacological prophylaxis of VTE in different ethnicities. Therefore, we aimed to evaluate the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wentao, Wei, Xinchun, Yang, Shiwei, Du, Changhong, Hu, Baoyue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	3900
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678573/ https://www.ncbi.nlm.nih.gov/pubmed/36401460 http://dx.doi.org/10.1097/MD.0000000000031948

Ejemplares similares

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis
por: Qureshi, Anjum, et al.
Publicado: (2017)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
por: Lazrak, Hind Harrak, et al.
Publicado: (2017)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Delayed prophylaxis with unfractionated heparin increases the risk of venous thromboembolic events in patients with moderate to severe traumatic brain injury: a retrospective analysis
por: Brandi, Giovanna, et al.
Publicado: (2020)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

Inhibition of Gastric Acid Secretion by Unfractionated and Low Molecular Weight Heparins in the Rat
por: Abdel Salam, Omar M.E., et al.
Publicado: (2006)

A direct comparison of prophylactic low-molecular-weight heparin versus unfractionated heparin in neurosurgery: A meta-analysis
por: Macki, Mohamed, et al.
Publicado: (2019)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Unfractionated heparin as a safe alternative in a case of low molecular weight heparin-induced thrombocytosis: A case report
por: Jabira, Salem, et al.
Publicado: (2021)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Effect of unfractionated and low molecular weight heparin on microcirculatory antithrombin effects during endotoxemia
por: Hoffmann, JN, et al.
Publicado: (2002)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin
por: Maharaj, Satish, et al.
Publicado: (2018)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Cartridge-Based Thromboelastography Can Be Used to Monitor and Quantify the Activity of Unfractionated and Low-Molecular-Weight Heparins
por: Dias, João D., et al.
Publicado: (2019)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
por: Seaman, Craig D., et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
por: Kim, Moo Hyun, et al.
Publicado: (2014)

Posterior Fossa Hemorrhage Following the Use of Low-Molecular-Weight Heparin: Lessons Learned and Recommendations for the Treatment and Prophylaxis of Postoperative Venous Thromboembolism
por: Naeem, Komal, et al.
Publicado: (2021)

Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis
por: Palamaner Subash Shantha, Ghanshyam, et al.
Publicado: (2015)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
por: Smrke, Alannah, et al.
Publicado: (2017)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing
por: Schurr, James W., et al.
Publicado: (2019)

THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents
por: Greiner, Jeanette, et al.
Publicado: (2019)

Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial
por: Haac, Bryce E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_30deovu71jbft1gptugsvkshjk